Dr. Ajaz Bulbul, MBBS, MD - Texas Tech University - MD

Dr. Ajaz Bulbul

MBBS, MD

Texas Tech University

MD

CARLSBAD, NM | United States

Main Specialties: Hematology & Oncology, Internal Medicine

ORCID logohttps://orcid.org/0000-0002-2728-8468


Top Author

Dr. Ajaz Bulbul, MBBS, MD - Texas Tech University - MD

Dr. Ajaz Bulbul

MBBS, MD

Introduction

Focused, innovative, and performance-driven professional with strong Hematology and Oncology background, with expertise in the delivery of anticancer drugs; interested in pursuing career in a challenging, stimulating, and fast-paced collaborative team environment. Able to develop a backbone of quality care through evidence-based practice and access to research and coordinated care with a quality cancer care team. I have developed two cancer clinics in Southeastern NM and successfully reduced the burden of travel and provided excellent care in a challenging rural environment. Strong background in conducting research participating in academic publishing, with proven ability of identifying goals and priorities while resolving key issues. Highly capable of interacting and establishing professional relationships with all levels of professionals.

Primary Affiliation: Texas Tech University - CARLSBAD, NM , United States

Specialties:


View Dr. Ajaz Bulbul’s Resume / CV

Education

Jul 2012
University of Southern California
MD/Fellowship
Jul 2012
University of Southern California
MD/Fellowship
Jul 2008
University of Southern California
MD/Residency

Publications

9Publications

50Reads

79Profile Views

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.

Cancer Res 2019 Feb 4;79(4):689-698. Epub 2019 Feb 4.

University of California San Diego, Moores Cancer Center, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-1281DOI Listing
February 2019
2 Reads
9.329 Impact Factor

Reasoning the effect of immunotherapy after chemoradiation in the PACIFIC trial.

Future Oncol 2019 Jan 3;15(1):81-94. Epub 2018 Sep 3.

Division of Internal Medicine, Department of Hematology/Oncology, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX 79409, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0464DOI Listing
January 2019
1 Read
2.480 Impact Factor

Lacrimal gland adenocarcinoma responding to checkpoint inhibition and androgen deprivation.

Authors:
Ajaz Bulbul

Oxf Med Case Reports 2018 Sep 25;2018(9):omy066. Epub 2018 Aug 25.

Division of Internal Medicine, Department of Hematology/Oncology, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/omcr/omy066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109195PMC
September 2018
13 Reads

The Conundrum of Adjuvant HER2 Treatment Options.

Front Oncol 2018 30;8:177. Epub 2018 May 30.

Division of Hematology Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2018.00177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989731PMC
May 2018
1 Read

First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?

Front Oncol 2018 10;8:94. Epub 2018 Apr 10.

University of California San Diego, Moores Cancer Center, La Jolla, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2018.00094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932412PMC
April 2018

Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations.

Sarcoma 2017 1;2017:1278268. Epub 2017 Nov 1.

Department of Pediatric Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/sarcoma/2017/1278268/
Publisher Site
http://dx.doi.org/10.1155/2017/1278268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687144PMC
November 2017
10 Reads

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.

Clin Genitourin Cancer 2016 10 6;14(5):450-456.e1. Epub 2016 Feb 6.

USC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.01.013DOI Listing
October 2016
23 Reads
1.693 Impact Factor

A. Bulbul, A. Mustafa, S. Chouial, S. Rashad; Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin’s lymphoma, Annals of Oncology, Volume 28, Issue 7, 1 July 2017, Pages 1675–1676,

View Article
3 Reads

Top co-authors

Hatim Husain
Hatim Husain

Moores Cancer Center

4
Ayesha Murtuza
Ayesha Murtuza

Center for Personalized Cancer Therapy

2
Sadaf Rashad
Sadaf Rashad

All Saints University of Medicine

2
Andrea Hayes-Jordan
Andrea Hayes-Jordan

University of Texas MD Anderson Cancer Center

1
Tanya B Dorff
Tanya B Dorff

University of Southern California

1
Asrar Mustafa
Asrar Mustafa

Acharya Shri Chander College of Medical Sciences and Hospital

1
Eila Skinner
Eila Skinner

University of Southern California

1
David I Quinn
David I Quinn

University of Southern California

1
Anne K Schuckman
Anne K Schuckman

University of Southern California

1